Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.97 |
| ▸ | GMNN | O75496 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | FPR2 | P25090 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695235 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| SCHEMBL166960 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL9895589 | 0.99 | MEN1 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| SCHEMBL12648358 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| SCHEMBL9927435 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL897995 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL30603259 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL30165585 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL29734979 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL9895302 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | UNIVERSITAET DES SAARLANDES (DE) | 2016-03-10 | — | — | US | disclosed |
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | UNIVERSITAET DES SAARLANDES (DE) | 2016-03-10 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8506945-B2 | Polymers with structure-defined functions | SMITH & NEPHEW, PLC. (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8188070-B2 | Method of treating neurological diseases and disorders | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188070-B2 | Method of treating neurological diseases and disorders | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110300096-A1 | Polymers With Structure-Defined Functions | GREENER BRYAN (GB) | 2011-12-08 | — | — | US | disclosed |
| US-7691847-B2 | Method of treating neurological diseases and disorders | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-04-06 | — | — | US | disclosed |
| US-20060135509-A1 | Method of treating neurological diseases and disorders | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2006-06-22 | — | — | US | disclosed |
| US-20050032929-A1 | Polymers with structure-defined functions | SMITH & NEPHEW, PLC (GB) | 2005-02-10 | — | — | US | disclosed |
| EP-1436334-A1 | POLYMERS WITH STRUCTURE-DEFINED FUNCTIONS | Smith & Nephew PLC (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004036181-A2 | METHOD OF TREATING NEUROLOGICAL DISEASES AND DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003027154-A1 | POLYMERS WITH STRUCTURE-DEFINED FUNCTIONS | SMITH & NEPHEW PLC (GB) | 2003-04-03 | — | — | WO | disclosed |
| US-6149945-A | Human fibroblast diffusable factors | ALBERTA CANCER BOARD (CA) | 2000-11-21 | — | — | US | disclosed |
| US-6117822-A | AS HERBICIDES AND PLANT DESICCANTS AND/OR DEFOLIANTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-12 | — | — | US | disclosed |
| EP-0980256-A2 | THE USE OF BIOLOGICALLY ACTIVE SUBSTANCES FOR INFLUENCING THE EXTRACELLULAR AREA OF SENSORY CELLS AND METHOD FOR CONTROLLING THE ADMINISTRATION OF ACTIVE SUBSTANCES AND DEVICE USED THEREIN | Eckmiller, Marion Sangster (DE) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050065-A2 | THE USE OF BIOLOGICALLY ACTIVE SUBSTANCES FOR INFLUENCING THE EXTRACELLULAR AREA OF SENSORY CELLS AND METHOD FOR CONTROLLING THE ADMINISTRATION OF ACTIVE SUBSTANCES AND DEVICE USED THEREIN | ECKMILLER MARION SANGSTER (DE) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | ATP2A2, ATP2A1, ATP2A3 | CYP3A4 4171/4885CYP1A2 2440/4885CYP2C19 3874/4885 |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | CYP3A4 4842/4885CYP1A2 4862/4885CYP2C19 4861/4885 |
| US-20110300096-A1 | Polymers With Structure-Defined Functions | MMP1, MMP8, ADAM12 | CYP3A4 694/4885CYP1A2 541/4885CYP2C19 353/4885 |
| US-20060135509-A1 | Method of treating neurological diseases and disorders | SMN1; SMN2, CLN6, PMP22 | CYP3A4 4805/4885CYP1A2 4361/4885CYP2C19 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.